Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in ASCVD and/or CKD
NCT07241390Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Primary completion
- Aug 2031
- Modality
- Small Molecules
- Countries
- 38
01
Overview
A Phase 3 trial of orforglipron in atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), sponsored by Eli Lilly and Company. Started Dec 2025; status: recruiting.
02
Drugs
orforglipron
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07241390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241390.